A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.
Open Access
- 15 May 1998
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 101 (10) , 2268-2277
- https://doi.org/10.1172/jci2068
Abstract
Myasthenia gravis (MG) is caused by helper T cell-dependent autoantibodies against the muscle acetylcholine receptor (AChR). Thymic epithelial tumors (thymomas) occur in 10% of MG patients, but their autoimmunizing potential is unclear. They express mRNAs encoding AChR alpha and epsilon subunits, and might aberrantly select or sensitize developing thymocytes or recirculating peripheral T cells against AChR epitopes. Alternatively, there could be defective self-tolerance induction in the abundant maturing thymocytes that they usually generate. For the first time, we have isolated and characterized AChR-specific T cell clones from two MG thymomas. They recognize extracellular epitopes (alpha75-90 and alpha149-158) which are processed very efficiently from muscle AChR. Both clones express CD4 and CD8alpha, and have a Th-0 cytokine profile, producing IL-4 as well as IFN-gamma. They are restricted to HLA-DP14 and DR52a; expression of these minority isotypes was strong on professional antigen-presenting cells in the donors' tumors, although it is generally weak in the periphery. The two clones' T cell receptor beta chains are different, but their alpha chain sequences are very similar. These resemblances, and the striking contrasts with T cells previously cloned from non-thymoma patients, show that thymomas generate and actively induce specific T cells rather than merely failing to tolerize them against self antigens.Keywords
This publication has 44 references indexed in Scilit:
- Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargetingImmunology Today, 1996
- Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes.Journal of Clinical Investigation, 1994
- Nicotinic Acetylcholine Receptor mRNAs in Myasthenic Thymuses: Association with Intrathymic Pathogenesis of Myasthenia GravisBiochemical and Biophysical Research Communications, 1993
- Suppression of Experimental Autoimmune Myasthenia Gravis by Epitope-Specific Neonatal Tolerance to Synthetic Region α146-162 of Acetylcholine ReceptorClinical Immunology and Immunopathology, 1993
- The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodiesMolecular Neurobiology, 1991
- Neoplastic epithelial cells express α-subunit of muscle nicotinic acetylcholine receptor in thymomas from patients with myasthenia gravisFEBS Letters, 1991
- Interleukin-4 mediates CDS induction on human CD4+ T-cell clonesNature, 1988
- Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin.The Journal of Experimental Medicine, 1986
- Myasthenia Gravis: Immunohistological heterogeneity in microenvironmental organization of hyperplastic and neoplastic thymuses suggesting different mechanisms of tolerance breakdownJournal of Neuroimmunology, 1986
- Direct demonstration of an HLA-DR allotypic determinant on the low molecular weight (beta) subunit using a mouse monoclonal antibody specific for DR3The Journal of Experimental Medicine, 1982